Mink therapeutics, inc.INKT.US Overview

US StockHealthcare

(No presentation for INKT)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

INKT Overall Performance

INKT AI Analysis & Strategy

INKT Recent Performance

-1.42%

Mink therapeutics, inc.

1.30%

Avg of Sector

0.61%

S&P500

INKT PowerScanner

INKT Key Information

INKT Valuation Metrics

INKT Earnings Table

INKT Profile

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.